Figure 3

NEAT1_2 is most highly expressed in HER2-enriched and luminal B intrinsic breast cancer subtypes in three independent cohorts. (a–c) NEAT1_2 expression in PAM50 intrinsic breast cancer subtypes from patients of the Oslo2 (a), METABRIC (b), and TCGA (c) breast cancer cohorts. Subtypes were determined using the PAM50 algorithm. The Kruskal-Wallis test was used to calculate whether any groups are significantly different from each other and Wilcoxon Rank-Sum test was used in post-testing for significant differences between pairs of groups. (****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; ns, p > 0.05).